Intellia Therapeutics (NTLA) PT Raised to $24 at Wedbush, After Company Receives Authorization To Initiate Clinical Trial

October 19, 2020 1:29 PM EDT
Get Alerts NTLA Hot Sheet
Price: $165.25 +12.46%

Rating Summary:
    16 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten raised the price target on Intellia Therapeutics (NASDAQ: NTLA) to $24.00 (from $20.00) while maintaining a Neutral rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change